retatrutide glp-1 gip glucagon receptor agonist Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Triple GLP-1 / GIP /

However, phase I and II clinical trial results have shown that although retatrutide has promising results for weight loss, it may have a few side effects to consider

A critical point that Al Gore made in our recent podcast

Real Peptides is committed to providing the high-purity peptides to facilitate these important studies, helping you explore if you can combine tesamorelin and retatrutide

*Compounded medications are prepared at the direction of your Affinity healthcare provider and are not governed by the FDA

Fasting insulin and C-peptide both fell, indicating reduced pancreatic stress

Nausea was reported in a significant proportion of participants, particularly during the dose-escalation period (Jastreboff et al., 2023)